San Mateo, Calif. – November 5, 2024 – PrognomiQ – a healthcare company focused on harnessing the power of multi-omics data to transform the detection and early treatment selection and monitoring of cancer and other complex diseases – today announced the company’s Series D financing of $34 million led by Seer, Inc., with participation from a new, large, strategic investor in the Diagnostics segment as well as from existing investors, including Catalio Capital Management, aMoon, Invus and Bruker. The closing of this round brings PrognomiQ’s total funding to more than $135 million since the company was founded in September 2020.
Read the full article here.
January 8, 2024
PrognomiQ’s Latest Research Demonstrates the Potential of its Multi-omics Liquid Biopsy Platform in Early-Stage Detection of Lung Cancer
Read More
January 23, 2023
PrognomiQ’s Multi-omics Liquid Biopsy Platform Demonstrates Promising Results in Early-Stage Cancer Detection of Non-Small Cell Lung Cancer
Read More